Advice
following an abbreviated submission:
tiotropium (Spiriva® Respimat®) is accepted for use within NHSScotland.
Indication under review: as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
Tiotropium has previously been accepted for use in adult patients with asthma as add-on maintenance bronchodilator treatment.
Download detailed advice358KB (PDF)
Medicine details
- Medicine name:
- tiotropium (Spiriva Respimat)
- SMC ID:
- SMC2118
- Indication:
- As add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 14 January 2019